Exabis Library:

Welcome to the e-CCO Library!

Search by:

All Congress AbstractsCongress SlidesTools & SkillsVideos & Podcasts

Year: Category:

DOP070: The relationship between vedolizumab drug concentrations at or before week 6 and remission at week 14 in ulcerative colitis patients from GEMINI 1

Year: 2016

Source: ECCO '16 Amsterdam

Authors:

X. Roblin*¹, M.T. Osterman², S. Glover³, U. Navaneethan⁴, M. A. Popa⁵, T. Wyant⁶, A. James⁷, K. Lasch⁵, M. Rosario⁶

Created: Friday, 22 February 2019, 9:49 AM

DOP071: Comparison of endoscopic responses to adalimumab monotherapy and combination therapy with azathioprine in patients with Crohn's disease: a sub-analysis of DIAMOND trial

Year: 2017

Source: ECCO '17 Barcelona

Authors:

Watanabe K.^*1, Matsumoto T.², Motoya S.³, Hisamatsu T.⁴, Nakase H.⁵, Yoshimura N.⁶, Ishida T.⁷, Kato S.⁸, Nakagawa T.⁹, Nagahori M.¹⁰, Esaki M.¹¹, Matsui T.¹², Naito Y.¹³, Kanai T.¹⁴, Suzuki Y.¹⁵, Nojima M.¹⁶, Watanabe M.¹⁰, Hibi T.¹⁷

Created: Wednesday, 20 February 2019, 10:36 AM

DOP071: Tight control with adalimumab-based treatment is associated with improved quality of life outcomes in patients with moderate to severely active Crohn’s disease: data from CALM

Year: 2018

Source: ECCO '18 Vienna

Authors:

R. Panaccione¹*, J.-F. Colombel², P. Bossuyt³, F. Baert⁴, T. Vanasek⁵, A. Danalioglu⁶, G. Novacek⁷, A. Armuzzi⁸, W. Reinisch⁷, E. Neimark⁹, J. Petersson⁹, A.M. Robinson⁹, R.B. Thakkar⁹, N. Chen⁹, M. Skup⁹, W.-J. Lee⁹, G. D’Haens¹⁰

Created: Thursday, 21 February 2019, 9:14 AM

DOP071: Tight control with adalimumab-based treatment is associated with improved quality of life outcomes in patients with moderate to severely active Crohn's Disease: Data from CALM

Year: 2018

Source: ECCO'18 Vienna

Authors: Panaccione Remo

Created: Tuesday, 8 May 2018, 11:36 AM

Files: 1

DOP071: Tofacitinib plasma concentration monitoring is not needed for optimisation of induction therapy in moderate to severe ulcerative colitis: Results of pooled exposure-response analyses of Phase 3 induction studies

Year: 2016

Source: ECCO'16 DOP

Authors: Su C.

Ulcerative Colitis, therapeutic drug monitoring, tofacitinib

Files: 1

DOP071: Tofacitinib plasma concentration monitoring is not needed for optimisation of induction therapy in moderate-to-severe ulcerative colitis: results of pooled exposure-response analyses of Phase 3 induction studies

Year: 2016

Source: ECCO '16 Amsterdam

Authors:

A. Mukherjee¹, S. Tsuchiwata², C. Deng³, C. Vong⁴, R. Xie³, S.W. Martin⁴, D. Yu⁵, D. Woodworth⁵, W. Niezychowski⁵, C. Su*⁵

Created: Friday, 22 February 2019, 9:49 AM

DOP072: Achieving biochemical remission with adalimumab therapy using therapeutic drug monitoring: Results of a large prospective Crohn’s disease cohort

Year: 2018

Source: ECCO '18 Vienna

Authors:

N. Plevris, P. Jenkinson, C.S. Chuah, M. Lyons, R. Hall, G. Jones, E. Watson, I. Arnott, C. Lees

Created: Thursday, 21 February 2019, 9:14 AM

DOP072: Achieving biochemical remission with adalimumab therapy using therapeutic drug monitoring: Results of a large prospective Crohn’s Disease cohort

Year: 2018

Source: ECCO'18 Vienna

Authors: Plevris Nikolas

Created: Tuesday, 8 May 2018, 11:36 AM

Files: 1

DOP072: Assessment of the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) using central video review of colonoscopies in paediatric patients with ulcerative colitis: data from the Canadian Children IBD Network

Year: 2017

Source: ECCO '17 Barcelona

Authors:

Carman N.^*1, Huynh H.², Mouzaki M.³, Crowley E.³, Walsh C.M.³, Ricciuto A.³, Walters T.D.³, Church P.C.³

Created: Wednesday, 20 February 2019, 10:36 AM

DOP072: Assessment of the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) using central video review of colonoscopies in paediatric patients with Ulcerative Colitis: Data from the Canadian Children IBD Network

Year: 2017

Source: ECCO'17 Barcelona

Authors: Carman N.

Colonoscopy,Treat to target

Files: 1

DOP072: Association of ustekinumab trough concentrations with clinical, biochemical and endoscopic outcomes

Year: 2016

Source: ECCO'16 DOP

Authors: Kopylov U.

therapeutic drug monitoring, ustekinumab

Files: 1

DOP072: Association of ustekinumab trough concentrations with clinical, biochemical, and endoscopic outcomes

Year: 2016

Source: ECCO '16 Amsterdam

Authors:

R. Battat¹, U. Kopylov*², T. Bessissow¹, A. Bitton¹, A. Cohen³, M. Martel¹, E. G. Seidman⁴, W. Afif⁴

Created: Friday, 22 February 2019, 9:49 AM

DOP073: Incidental diagnosis of inflammatory bowel disease through bowel cancer screening: a 7-year experienceU. Nosegbe*¹, J. A. Scott¹, R. O. Butcher^{1, 2}, A. M. Abbasi¹, R. C. Prudham¹, R. George¹, J. Limdi^{1, 2}

Year: 2016

Source: ECCO '16 Amsterdam

Authors:

¹The Pennine Acute Hospitals NHS Trust, Manchester, United Kingdom, ²University of Manchester, Institute of Inflammation and Repair, Manchester Academic Health Sciences Centre, Manchester, United Kingdom

Created: Friday, 22 February 2019, 9:49 AM

DOP073: Results of the sixth ECCO Scientific Workshop: The pathogenesis of inflammatory extraintestinal manifestations of Inflammatory Bowel Disease - implications for research, diagnosis and therapy

Year: 2018

Source: ECCO'18 Vienna

Authors: Hedin Charlotte R H

Created: Tuesday, 8 May 2018, 11:36 AM

Files: 1

DOP073: Results of the sixth ECCO Scientific Workshop: The pathogenesis of inflammatory extraintestinal manifestations of inflammatory bowel disease: implications for research, diagnosis, and therapy

Year: 2018

Source: ECCO '18 Vienna

Authors:

C.R.H. Hedin¹*, S.R. Vavricka², A.J. Stagg³, A. Schoepfer⁴, T. Raine⁵, L. Puig⁶, U. Pleyer⁷, A. Navarini⁸, A.E. van der Meulen - de Jong⁹, J. Maul¹⁰, K.H. Katsanos¹¹, A. Kagramanova¹², T. Greuter¹³,¹⁴, Y. Gonzalez Lama¹⁵, F.A. van Gaalen¹⁶, P. Ellul¹⁷, J. Burisch¹⁸, D. Bettenworth¹⁹, M. Becker²⁰, G. Bamias²¹, F. Rieder²²

Created: Thursday, 21 February 2019, 9:14 AM

DOP073: Submucosal injection of the oligonucleotide STNM01 is able to induce clinical remission, mucosal healing and histological response in left-sided Ulcerative Colitis patients with moderate-to-severe disease

Year: 2017

Source: ECCO'17 Barcelona

Authors: Atreya R.

Ulcerative colitis, Firoblast, Lymphocyte

Files: 1

DOP073: Submucosal injection of the oligonucleotide STNM01 is able to induce clinical remission, mucosal healing and histological response in left-sided ulcerative colitis patients with moderate-to-severe disease

Year: 2017

Source: ECCO '17 Barcelona

Authors:

Atreya R.^*1, Kühbacher T.^2,3, Waldner M.J.¹, Hirschmann S.¹, Drvarov O.², Abu Hashem R.², Maaser C.⁴, Kucharzik T.⁴, Dinter J.⁵, Schramm C.⁵, Mertens J.⁵, Holler B.⁶, Mössner J.⁶, Suzuki K.⁷, Yokoyama J.⁷, Terai S.⁷, Yoneyama H.⁸, Asakura H.⁷, Hibi T.⁹, Neurath M.F.¹

Created: Wednesday, 20 February 2019, 10:36 AM

DOP074: IL-33 promotes gut mucosal wound healing by inducing miRNA-320 to stimulate epithelial restitution and repair

Year: 2018

Source: ECCO'18 Vienna

Authors: Lopetuso Loris Riccardo

Created: Tuesday, 8 May 2018, 11:36 AM

Files: 1

DOP074: IL-33 promotes gut mucosal wound healing by inducing miRNA-320 to stimulate epithelial restitution and repair

Year: 2018

Source: ECCO '18 Vienna

Authors:

L.R. Lopetuso¹,²*, C. De Salvo², L. Di Martino², N. Rana², W. Goodman², F. Scaldaferri¹, A. Armuzzi¹, A. Gasbarrini¹, T.T. Pizarro²

Created: Thursday, 21 February 2019, 9:14 AM

DOP074: Incidence and prediction of fistula formation in England

Year: 2016

Source: ECCO '16 Amsterdam

Authors:

K. Sahnan*¹, A. Askari¹, S. Adegbola*¹, P. Tozer¹, R. Phillips¹, A. Hart², O. Faiz¹

Created: Friday, 22 February 2019, 9:49 AM